subscribeSubscribe
Enforcement Report - Week of April 12, 2023

Enforcement Report - Week of April 12, 2023
FDA
12 Apr 2023
Share Share
Enforcement Report - Week of March 8, 2023

Enforcement Report - Week of March 8, 2023
FDA
08 Mar 2023
Share Share
JB Pharma acquires cardiac brand from Glenmark for Rs 314 crore

JB Pharma acquires cardiac brand from Glenmark for Rs 314 crore
Viswanath Pilla ECONOMIC TIMES
15 Dec 2022
Share Share
FDA Issues Untitled Letter to Althera for Statements Relating to ROSZET

FDA Issues Untitled Letter to Althera for Statements Relating to ROSZET
Dominick & Arushi LEXBLOG
24 Jun 2022
Share Share
FDA slams Althera for misleading ad with dearth of safety info & dubious stats

FDA slams Althera for misleading ad with dearth of safety info & dubious stats
Z. Brennan ENDPTS
08 Jun 2022
Share Share
Now Available: Generic Ezetimibe-Rosuvastatin Combination Tablets - In A Trial

Now Available: Generic Ezetimibe-Rosuvastatin Combination Tablets - In A Trial
EINNEWS
15 Nov 2021
Share Share
Class 4 Medicines Defect Information:Rosuvastatin 5 mg, 10 mg, 20 mg and 40 mg

Class 4 Medicines Defect Information:Rosuvastatin 5 mg, 10 mg, 20 mg and 40 mg
PSNC
10 Sep 2021
Share Share
FDA Approves Althera’s Roszet (rosuvastatin and ezetimibe)

FDA Approves Althera’s Roszet (rosuvastatin and ezetimibe)
PRWEB
31 Mar 2021
Share Share
Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™

Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™
PRNEWSWIRE
09 Feb 2021
Share Share
AZ sells rights to statin med Crestor to Grünenthal

AZ sells rights to statin med Crestor to Grünenthal
Lucy Parsons PHARMATIMES
02 Dec 2020
Share Share